- Home
- ENLT vs AKRO Comparison
ENLT vs AKRO Comparison
Compare ENLT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- AKRO
- Stock Information
- Founded
- ENLT 2008
- AKRO 2017
- Country
- ENLT Israel
- AKRO United States
- Employees
- ENLT N/A
- AKRO N/A
- Industry
- ENLT
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- AKRO Health Care
- Exchange
- ENLT Nasdaq
- AKRO Nasdaq
- Market Cap
- ENLT 1.9B
- AKRO 2.0B
- IPO Year
- ENLT 2023
- AKRO 2019
- Fundamental
- Price
- ENLT $17.33
- AKRO $28.08
- Analyst Decision
- ENLT Buy
- AKRO Strong Buy
- Analyst Count
- ENLT 4
- AKRO 8
- Target Price
- ENLT $19.00
- AKRO $46.83
- AVG Volume (30 Days)
- ENLT 24.1K
- AKRO 594.3K
- Earning Date
- ENLT 02-24-2025
- AKRO 02-27-2025
- Dividend Yield
- ENLT N/A
- AKRO N/A
- EPS Growth
- ENLT N/A
- AKRO N/A
- EPS
- ENLT 0.41
- AKRO N/A
- Revenue
- ENLT $358,416,000.00
- AKRO N/A
- Revenue This Year
- ENLT $428.35
- AKRO N/A
- Revenue Next Year
- ENLT $27.54
- AKRO N/A
- P/E Ratio
- ENLT $41.89
- AKRO N/A
- Revenue Growth
- ENLT 47.65
- AKRO N/A
- 52 Week Low
- ENLT $14.09
- AKRO $15.32
- 52 Week High
- ENLT $18.61
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- ENLT 60.95
- AKRO 41.87
- Support Level
- ENLT $16.71
- AKRO $27.45
- Resistance Level
- ENLT $17.34
- AKRO $28.76
- Average True Range (ATR)
- ENLT 0.42
- AKRO 1.49
- MACD
- ENLT 0.12
- AKRO -0.12
- Stochastic Oscillator
- ENLT 83.48
- AKRO 17.98
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. It operates across the three largest renewable segments namely solar, wind and energy storage. Geographically, it operates in the United States, Israel and 9 European countries.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.